|
|
||||||||||||||
|
|
|||||||||||||||
COMMENTARY |
| FDA legislation |
Correspondence to:
Dr Michael S Givel
Department of Political Science, University of Oklahoma, 455 West Lindsey, Room 205, Norman, OK 73019, USA; mgivel@ou.edu
Keywords: Food and Drug Administration legislation; regulatory policy; tobacco consumption
| The first 150 words of the full text of this article appear below. |
Since 2004, a highly unusual annual spectacle has occurred with the introduction in Congress of similar US Food and Drug Administration (FDA) tobacco regulation bills. Often accompanied by considerable controversy and animosities, these FDA tobacco bills have always been supported by the tobacco giant Philip Morris along with numerous health groups including the Campaign for Tobacco-Free Kids, American Heart Association, American Lung Association, and American Cancer Society. At the centre of this controversy have been two important policy issues and questions. Firstly, why would a giant tobacco company actually campaign to be more stringently regulated? Secondly, given the history of tobacco industry disease, deception, and duplicity why would anti-tobacco advocates actually believe that this is in the best interest of public health and even public health advocacy?
The origins of this modern controversy began in 1996 when the FDA issued a final rule regulating tobacco as a drug
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |